Tony S. Mok, MD, Talks Future Analyses of Capmatinib Plus Pembrolizumab in NSCLC


Tony S. Mok, MD, spoke about future research efforts focused on capmatinib plus pembrolizumab in patients with previously untreated MET-unselected, PD-L1–positive non–small cell lung cancer.

CancerNetwork® spoke with Tony S. Mok, MD, Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and chair of Clinical Oncology at the Chinese University of Hong Kong, at the 2022 American Society of Clinical Oncology Annual Meeting about future analyses of pembrolizumab (Keytruda) plus capmatinib (Tabrecta) after results from a phase 2 trial (NCT04139317) in patients with MET-unselected, PD-L1–positive previously untreated non–small cell lung cancer failed to show an advantage of the combination.

Results from this trial indicated that capmatinib did not improve antitumor activity, but Mok notes that negative trials are important in the lung cancer space as it allows clinicians to learn from the results.


We have made a very good hypothesis, but I think there’s 1 point that we neglected to look into in great detail. When we looked at the dose of capmatinib, we were using the dose that is supposed to inhibit the cancer cell MET expression. This is mostly [found] in the patient with either MET amplification or MET 14 skipping [mutation]. That’s what the drug was designed for. The question is that we have not actually investigated is the dose required to moderate the T cell. We had a dose issue where it may or may not be feasible in the future to use the same drug combination. The concept is not exactly gone yet. We may have to go back to the drawing board to determine how best to moderate the T cell with the MET inhibitor in the future.

This is a negative study, but we can always learn from the negative studies. First, the concept itself is a good one. That’s why we get engaged with it. However, [regarding] the dosing part, we did not address it. Before we engage in it, we automatically [choose] the standard dose which is easier in that way. Again, we have to learn from the fact that dosing potentially may affect the outcome.

Editor's Note: In this video, the institution should be listed as "The Chinese University of Hong Kong."


Mok T, Cortinovis D, Majem M, et al. Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study. J Clin Oncol. 2022;40(suppl 16):9118. doi:10.1200/JCO.2022.40.16_suppl.9118

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Expert on NSCLC
Related Content